孟玮,张烁

• 1:哈尔滨医科大学附属第二医院心血管病科

摘要(Abstract)：

<正>高血压是影响心脑血管病发病率和死亡率最常见的慢性疾病[1]。5%~30%的患者需服用3种或3种以上降压药(至少含有一种利尿剂),且每种药物均已达到最佳剂量而不能控制的血压,称为顽固性高血压(resistant hypertension,r HTN)[2-4]。尽管药物研制发展迅速,顽固性高血压的发生率仍不断增长,在合并动脉粥样硬化的患者中尤其常见,亟需有效治疗方案[4-5]。交感神经过度激活与本病发病密切相

关键词(KeyWords)： 交感神经;肾动脉消融;顽固性高血压

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 孟玮,张烁

参考文献(References)：

• [1]Kearney PM,Whelton M,Reynolds K,et al.Global burden of hypertension:analysis of worldwide data.Lancet,2005,365:217-223.
• [2]Calhoun DA,Jones D,Textor S,et.al.Resistant hypertension:diagnosis evaluation and treatment:a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.Circulation.2008,117:e510-e526.
• [3]孙宁玲,霍勇,王继光,等.难治性高血压诊断治疗中国专家共识.中国介入心脏病学杂志,2013,21:69-74.
• [4]Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC Guidelines for the management of arterial hypertension:the Task Force for the Management of Arteria Hypertension of the European Society of Hypertension(ESH)and of the Eruopean Society of Cardiology(ESC).Eur Heart J,2013,34:2159-2219.
• [5]Kumbhani DJ,Steg PG,Cannon CP,et al.Resistant hypertension:a frequent and ominous finding among hypertensive patients with atherothrombosis.Eur Heart J,2013,34:1204-1214.
• [6]Schmieder RE,Redon J,Grassi G,et al.ESH position paper:renal denervation-an interventional therapy of resistant hypertension.J Hypertens,2012,30:837-841.
• [7]霍勇,龚艳君.经导管去肾交感神经治疗顽固性高血压.中国介入心脏病学杂志,2012,20:61-62.
• [8]Mahfoud F,Lüscher TF,Andersson B,et al.Expert consensus document from the European Society of Cardiology on catheterbased renal denervation.Eur Heart J,2013,34:2149-2157.
• [9]Esler M.The 2009 Carl Ludwig Lecture:Pathophysiology of the human sympathetic nervous system in cardiovascular diseases:the transition from mechanisms to medical management.J Appl Physiol(1985),2010,108:227-237.
• [10]Hering D,Esler MD,Krum H,et al.Recent advances in the treatment of hypertension.Expert Rev Cardiovasc Ther,2011,9:729-744.
• [11]Harmar P,Kokeny G,Liptak P,et al.The Combination of ACE Inhibition plus Sympathetic Denervation Is Superior to ACE Inhibitor Monotherapy in the Rat Renal Ablation Model.Nephron Exp Nephrol,2007,105:e124-e136.
• [12]O'Hagan KP,Thomas GD,Zambraski EJ,et al.Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension.Am J Hypertens,1990,3:62-64.
• [13]Smithwick RH,Thompson JE.Splanchnicectomy for essential hypertension;results in 1,266 cases.J Am Med Assoc,1953,152:1501-1504.
• [14]Sakakura K,Ladich E,Cheng Q,et al.Anatomical assessment of sympathetic peri-arterial renal nerves in man.J Am Coll Cardiol.2014,64:635-643.
• [15]Mahfoud F,Schlaich M,Kindermann I,et al.Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension:a pilot study.Circulation,2011,123:1940-1946.
• [16]Krum H,Schlaich M,Whitbourn R,et al.Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study.Lancet,2009,373:1275-1281.
• [17]Esler MD,Krum H,Sobotka PA,et al.Renal sympathetic denervation in patients with treatment-resistant hypertension(the Symplicity HTN-2 trial):a randomized controlled trial.Lancet,2010,376:1903-1909.
• [18]Symplicity HTN-1 Investigators.Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months.Hypertension,2011,57:911-917.
• [19]Krum H,Schlaich MP,Sobotka PA,et al.Percutaneous renal denervation in patients with treatment-resistant hypertension:final 3-year report of the Symplicity HTN-1 study.Lancet,2013,383:622-629.
• [20]Esler MD,Krum H,Schlaich M,et al.Renal sympathetic denervation for treatment of drug-resistant hypertension:one-year results from the Symplicity HTN-2 randomized,controlled trial.Circulation,2012,126:2976-2982.
• [21]Bhatt DL,Kandzari DE,O'Neill WW,et al.A controlled trial of renal denervation for resistant hypertension.N Engl J Med,2014,370:1393-1401.
• [22]Worthley SG,Tsioufis CP.Worthley MI,et al.Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension:the Enlig HTN I trial.Eur Heart J,2013,34:2132-2140.
• [23]Mahfoud F,Ukena C,Schmieder RE,et al.Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.Circulation,2013,128:132-140.
• [24]Fadl Elmula FE,Hoffmann P,Fossum E,et al.Renal Sympathetic Denervation in patients with treatmentresistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure.Hypertension,2013,62:526-532.
• [25]Bohm M.SYMPLICITY Registry Data Spur Further Debate on Role of Renal Denervation.Washington:American College of Cardiology(ACC),2014.
• [26]Prochnau D,Heymel S,Gobel B,et al.Resistant hypertension:multivariate predictors of blood pressure response to renal denervation.Int J Cardiol,2013,168:3130-3132.
• [27]Prochnau D,Heymel S,Otto S,et al.Renal denervation with cryoenergy as second-line option is effective in the treatment of resistant hypertension in non-responders to radiofrequency ablation.Euro Intervention,2014,10:640-655.
• [28]Patel HC,Dhillon PS,Mahfoud F,et al.The biophysics of renal sympathetic denervation using radiofrequency energy.Clin Res Cardiol,2014,103:337-344.
• [29]Rippy MK,Zarins D,Barman NC,et al.Catheter-based renal sympathetic denervation:chronic preclinical evidence for renal artery safety.Clin Res Cardiol,2011,100:1095-1101.
• [30]Fagard RH,Celis H,Thijs L,et al.Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension.Hypertension,2008,51:55-61.
• [31]Sega R,Facchetti R,Bombelli M,et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population:follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni(PAMELA)study.Circulation,2005,111:1777-1783.
• [32]Persu A,Jin Y,Azizi M,et al.Blood pressure changes after renal denervation at 10 European expert centers.J Hum Hypertens,2014,28:150-156.
• [33]Dorr O,Liebetrau C,Mollmann H,et al.Soluble fms-Like Tyrosine Kinase-1 and Endothelial Adhesion Molecules(Intercellular Cell Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1)as Predictive Markers for Blood Pressure Reduction After Renal Sympathetic Denervation.Hypertension,2014,63:984-990.